Sunil Healthcare
BSE: SUNLOC · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Sunil Healthcare's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Sunil Healthcare Limited is an Indian manufacturer specialising in empty hard capsules, including gelatin and HPMC vegetable variants, for the pharmaceutical and dietary supplement sectors. The company operates manufacturing facilities in Rajasthan and maintains a global export presence across North America, Europe, Africa, and Southeast Asia.
Business Model
The company generates revenue through the large-scale production and sale of pharmaceutical-grade capsules and has diversified into wellness and nutritional supplements under the Sunloc brand. It leverages established distribution networks and adheres to international quality certifications like WHO-GMP to maintain its market position.
Growth Outlook
Growth is driven by the expansion of the company's product portfolio into specialized capsule variants and the leveraging of its distribution network to scale the Sunloc wellness brand. Continued focus on international quality standards supports its strategy to increase penetration in global pharmaceutical markets.
Key Risks
- Regulatory Compliance. Failure to maintain international certifications like WHO-GMP could severely restrict access to key export markets.
- Raw Material Price Volatility. Fluctuations in the cost of gelatin and other raw materials directly impact the manufacturing margins of capsule products.
- Competitive Pressure. The pharmaceutical packaging sector is highly competitive, with pricing pressures from both domestic and international manufacturers.
- Geopolitical and Currency Risk. As a significant exporter, the company is exposed to currency fluctuations and trade policy changes in its diverse global markets.
Start your research today
Unlock AI insights, financials, peers and live data on Sunil Healthcare and 5,000+ companies — free.
Key Metrics
REVENUE
₹88 Cr
TTM · consolidated
NET PROFIT
₹4 Cr
TTM · consolidated
EPS
₹3.91
TTM · consolidated
RETURN ON EQUITY
5.9%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
10.4%
TTM · consolidated
P/E
17.3x
Q4 FY26 · consolidated
EV/EBITDA
7.0x
Q4 FY26 · consolidated
EBITDA MARGIN
18.9%
TTM · consolidated
NET PROFIT MARGIN
7.7%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.8x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Sunil HealthcareSUNLOC | ₹78 Cr | 19.42 | 8.05 | 5.2% | 18.9% | 5.9% | 10.4% | +3.8% |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Q4 FY26
Financials
Sunil Healthcare
BSE: SUNLOC · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Sunil Healthcare's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Sunil Healthcare Limited is an Indian manufacturer specialising in empty hard capsules, including gelatin and HPMC vegetable variants, for the pharmaceutical and dietary supplement sectors. The company operates manufacturing facilities in Rajasthan and maintains a global export presence across North America, Europe, Africa, and Southeast Asia.
Business Model
The company generates revenue through the large-scale production and sale of pharmaceutical-grade capsules and has diversified into wellness and nutritional supplements under the Sunloc brand. It leverages established distribution networks and adheres to international quality certifications like WHO-GMP to maintain its market position.
Growth Outlook
Growth is driven by the expansion of the company's product portfolio into specialized capsule variants and the leveraging of its distribution network to scale the Sunloc wellness brand. Continued focus on international quality standards supports its strategy to increase penetration in global pharmaceutical markets.
Key Risks
- Regulatory Compliance. Failure to maintain international certifications like WHO-GMP could severely restrict access to key export markets.
- Raw Material Price Volatility. Fluctuations in the cost of gelatin and other raw materials directly impact the manufacturing margins of capsule products.
- Competitive Pressure. The pharmaceutical packaging sector is highly competitive, with pricing pressures from both domestic and international manufacturers.
- Geopolitical and Currency Risk. As a significant exporter, the company is exposed to currency fluctuations and trade policy changes in its diverse global markets.
Start your research today
Unlock AI insights, financials, peers and live data on Sunil Healthcare and 5,000+ companies — free.
Key Metrics
REVENUE
₹88 Cr
TTM · consolidated
NET PROFIT
₹4 Cr
TTM · consolidated
EPS
₹3.91
TTM · consolidated
RETURN ON EQUITY
5.9%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
10.4%
TTM · consolidated
P/E
17.3x
Q4 FY26 · consolidated
EV/EBITDA
7.0x
Q4 FY26 · consolidated
EBITDA MARGIN
18.9%
TTM · consolidated
NET PROFIT MARGIN
7.7%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.8x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
As of Q4 FY26